Summit-logo-RGB.png
Summit Therapeutics Inc. Reports Financial Results and Operational Progress for the Third Quarter and Nine Months Ended September 30, 2022
09 nov. 2022 08h30 HE | Summit Therapeutics Inc.
Menlo Park, California, Nov. 09, 2022 (GLOBE NEWSWIRE) -- Summit Therapeutics Inc. (NASDAQ: SMMT) ("Summit," "we," or the "Company") today reports its financial results and provides an update on...
Summit-logo-RGB.png
Summit Therapeutics Presents Ri-CoDIFy Trial Results for Microbiome-Sparing Ridinilazole at IDWeek 2022
20 oct. 2022 17h15 HE | Summit Therapeutics Inc.
Ridinilazole resulted in a 53% relative risk reduction in recurrence of C. difficile infection compared to treatment with vancomycin Ridinilazole preserved the gut microbiome compared to...
Summit-logo-RGB.png
Summit Therapeutics to Present Ri-CoDIFy Trial Results for Microbiome-Sparing Ridinilazole at IDWeek 2022
13 oct. 2022 08h00 HE | Summit Therapeutics Inc.
Menlo Park, California, Oct. 13, 2022 (GLOBE NEWSWIRE) -- Summit Therapeutics Inc. (NASDAQ: SMMT) (“Summit,” “we,” or the “Company”) and its product candidate, ridinilazole, will have an oral podium...
Summit-logo-RGB.png
Summit Therapeutics Inc Reports Financial Results and Operational Progress for the Second Quarter Ended June 30, 2022
11 août 2022 08h00 HE | Summit Therapeutics Inc.
Menlo Park, California, Aug. 11, 2022 (GLOBE NEWSWIRE) -- Summit Therapeutics Inc. (NASDAQ: SMMT) ("Summit," "we," or the "Company") today reports its financial results and provides an update on...
Summit-logo-RGB.png
Summit Therapeutics Closes Fully-Subscribed $100 Million Rights Offering
09 août 2022 13h37 HE | Summit Therapeutics Inc.
Menlo Park, California, Aug. 09, 2022 (GLOBE NEWSWIRE) -- Summit Therapeutics Inc. (NASDAQ: SMMT) (“Summit,” "we," or the “Company”) today announced the successful closing of its fully-subscribed...
Summit-logo-RGB.png
Summit Therapeutics Appoints Dr. Maky Zanganeh as Co-CEO & President
26 juil. 2022 16h15 HE | Summit Therapeutics Inc.
Menlo Park, California, July 26, 2022 (GLOBE NEWSWIRE) -- Summit Therapeutics Inc. (NASDAQ: SMMT) announces that Dr. Maky Zanganeh, DDS, MBA, has been appointed as Co-Chief Executive Officer &...
Summit-logo-RGB.png
Summit Therapeutics Announces Commencement of $100 Million Rights Offering
18 juil. 2022 16h05 HE | Summit Therapeutics Inc.
Menlo Park, CA, July 18, 2022 (GLOBE NEWSWIRE) --  Summit Therapeutics Inc. (NASDAQ: SMMT) today announced that it has commenced its previously-announced rights offering of up to $100 million of the...
Summit-logo-RGB.png
Summit Therapeutics Provides Update on Ridinilazole
14 juil. 2022 08h30 HE | Summit Therapeutics Inc.
Menlo Park, CA, July 14, 2022 (GLOBE NEWSWIRE) -- Summit Therapeutics Inc. (NASDAQ: SMMT) (“Summit,” "we," or the “Company”) today provided an update with respect to the clinical development of...
Summit-logo-RGB.png
Summit Therapeutics Announces $100 Million Rights Offering
22 juin 2022 16h30 HE | Summit Therapeutics Inc.
Menlo Park, CA, June 22, 2022 (GLOBE NEWSWIRE) -- Summit Therapeutics Inc. (NASDAQ: SMMT) (“Summit” or the “Company”) today announced that the Company’s Board of Directors has approved a rights...
Summit-logo-RGB.png
Summit Therapeutics Inc Reports Financial Results and Operational Progress for the First Quarter Ended March 31, 2022
11 mai 2022 16h30 HE | Summit Therapeutics Inc.
Cambridge, MA, May 11, 2022 (GLOBE NEWSWIRE) -- Summit Therapeutics Inc. (NASDAQ: SMMT) ("Summit," "we," or the "Company") today reports its financial results and provides an update on operational...